Cardiovalve 完成了 150 名患者的三尖瓣试验的入组，目标是 2027 年在欧洲推出。 Cardiovalve completes enrollment in its tricuspid valve trial with 150 patients, aiming for a 2027 European launch.

维纳斯医疗技术公司的子公司Cardiovalve已完成其关键的TARGET试验,该试验涉及150名患者的跨导管三门置换系统. Cardiovalve, a subsidiary of Venus Medtech, has completed enrollment in its pivotal TARGET trial for a transcatheter tricuspid valve replacement system, with 150 patients. 该公司计划于2025年底提交CE Mark申请,可能到2027年欧洲商业发射。 The company plans to submit a CE Mark application in late 2025, with potential European commercial launch by 2027. 它还正在准备启动AHEAD研究,以建立下一代双向阀门更换系统,预期在2025年TCT会议上提供早期数据。 It is also preparing to launch the AHEAD study for a next-generation mitral valve replacement system, with early data expected at the TCT 2025 conference. 该公司拥有150多个专利和全球研发中心,侧重于最少侵入性心脏阀门治疗。 The company, which has over 150 patents and global R&D centers, focuses on minimally invasive heart valve therapies.